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ease progression. Real-world data on actual health care resource consumption and
patient clinical characteristics are used. Time horizon of themodels should be long
enough to capture meaningful differences in outcomes. The differential clinical
attributes of the products are identified and direct links are established with the
corresponding economic values. The resulting impact on disease progression and
consequences for consumption of health care resources are simulated. The pri-
mary output is the cost-avoidance against the chosen comparator, with corre-
sponding breakdown by each clinical attribute. RESULTS: CCEV directly translates
the differences in clinical outcomes to the differences in economic values. This
methodology has been effectively applied in the decision process at different
stages of drug development, such as, to prioritize pipeline assets by comparing the
potential economic value of assets under development and quantifying the value
of each differentiated output. These insights are used to guide and design the
following data generation strategies. CONCLUSIONS: CCEV methodology directly
translates clinical outcomes to economic values and is a practical PE tool for deci-
sion makers. It can be employed across the entire product life-cycle, starting from
the early stages of drug development.
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Minimal Clinically Important Difference margins (MCIDs) are being applied by re-
imbursement agencies to assess the non-inferiority of new medications against
comparator medications in the Asia Pacific Region. If a new medication is deemed
non-inferior to an all ready reimbursed medication either via direct or indirect
comparison methods the newer product is generally reimbursed at the same price
as the comparator medication (ie. through cost-minimisation). The concept of an
MCID margin for survival outcomes, however, is problematic and controversial. A
superficial consideration of MCIDs for survival outcomes may lead to the conclu-
sion that the MCID for survival is inappropriate and no difference in survival is
acceptable. As such, the MCID for survival should be zero. In this case such an
analysis would become a superiority analysis. If this approach to the assessment of
such products were to prevail, new products with a high likelihood of affording
patients a survival benefit compared to their comparator products may be rejected
even on a cost-minimisation basis. Instead, where the point estimate of treatment
effect favours the new treatment serious consideration should be given to reim-
bursing the new product at the same or higher price. Using indirect comparison
methods and real world hazard ratio data this research introduces the concept of
MCID-cumulative acceptability curves (MCID-CAC) as an aid to making pragmatic
reimbursement decisions for new products that may extend patients lives.
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OBJECTIVES: This meta-analysis aims to assess the potential risk of osteonecrosis
of jaw and bisphosphonate use in cancer patients . METHODS: The published
literature was systematically searched and reviewed usingMEDLINE (1950 through
July 2011), EMBASE (1980 through July 2011), and the Cochrane Central Register of
Controlled Trials (The Cochrane Library 2011 issue 1). Studies that included specific
risk estimates were pooled using a random-effects model. The bias and quality of
these studies were assessed with RevMan statistical software (version 5.0) and the
GRADEmethod of the Cochrane Collaboration. RESULTS: A total of 32 publications
met inclusion criteria, but only 9 studies that included 51580 subjects for analysis.
No randomized controlled clinical trials, meta-analysis or quality of life articles
were found that contained data for risks or prevalence of osteonecrosis. The results
of a meta-analysis that pooled data from 10 cohort studies indicated that the over-
all multivariable odds ratio and hazard ratio were 1.11 (95% CI: 0.15, 8.47 ) and 0.35,
23835 , respectively (95% CI 0.51 to 1.00; p  1.00), respectively. The risk of osteo-
necrosis associated with biophosphonate was statistically significant. The results
of the quality assessment of these studies indicated low scores using the GRADE
method. CONCLUSIONS: The uses of bisphosphonates is likely to be associated
with the increased risk of osteonecrosis of jaw in cancer patients.
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THE RELATIONSHIP OF FOLLOWING LIPID-LOWERING DRUGS USED WITH
ADJUVANT HORMONAL THERAPY IN BREAST CANCER WOMEN
Chang YC1, Lin SJ2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kohsiung Medical University, Kaohsiung,
Kaohsiung, Taiwan
OBJECTIVES: Extended adjuvant hormonal therapywith aromatase inhibitors (AIs)
or tamoxifen can both effectively reduce the recurrence of breast cancer, but the
potential of change lipid profile with AIs compared to tamoxifen was observed in
some clinical studies. The aim of this study was to evaluate whether the hormone
adjuvant therapywill increase the prescribing rate of lipid-lowering drugs (LLDs) in
breast cancer women. METHODS: A retrospective cohort study was conducted
using the National Health Insurance Research Database between January 1997 and
December 2008. The inclusion criteria were adult women who were newly diag-
nosed with breast cancer and without past history of hyperlipidemia or other can-
cer diseases between 1998 and 2008. The study endpoint was defined as emerging
of the first prescription of LLDs within the exposure period. Adjusted hazard ratio
(HR) for the first LLDs prescription was analyzed using multivariable Cox propor-
tional hazards regression model. RESULTS: There were 378, 1148 and 756 breast
cancer patients treated with AIs, tamoxifen and didn’t receive hormonal therapy,
respectively. Compared to the non-hormonal therapy cohort, the rate of prescrib-
ing LLDs was lower in patients who treated with tamoxifen after adjusted age and
comorbidity (HR0.68, [95% CI0.46-0.99]), and non-significantly increased in pa-
tients who treated with AIs (HR1.12 [95% CI0.65-1.91]). In addition, the prescrib-
ing LLDs rate between AIs treatment and treatment with tamoxifen was non-
significantly increased (HR1.41 [95% CI0.83-2.83]) in the head to head
comparison. CONCLUSIONS: Results from this study indicated that AIs does not
significantly increase the risk of prescribing LLDs compare to the patients without
hormonal therapy. In contract, the tamoxifen therapy was significantly reduced
the prescription rate of LLDs, thus tamoxifen might had potential benefit on lipid
metabolism.
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OBJECTIVES: Colorectal Cancer (CRC) has now become the second leading cause of
death in Taiwan, and is one of the cancers with highest incidence in women. Our
goal is to integrate comprehensive information to determine the relation between
omics and clinical pathology by a systematic biomedical approach and further
improve our third generation gene chips for higher sensitivity and specificity to-
ward colorectal cancer.METHODS: : One hundred and five patients colorectal can-
cer patients who had undergone curative surgical resection of colorectal cancer
were studied. The copy number for each SNP probe set taken from a tumor sample
was calculated by comparing the probe intensity to the reference probe intensity
from non-neoplastic tissue, and creating a list of the genome-wide copy number
data. RESULTS: Among 105 patients with a median follow-up period of 5.6 years
(range, 4.1-10.8 years), 23 developed early disease recurrence, whereas 82 did not.
Most of themweremale and less than 60 years (p0.044). Stage III, deeper invasive
tumor (T3 T4) and positive lymph node metastasis could be found seriously by
70.5%, 92.4%, and 68.6%, respectively. CEA, EV12B, ATP2A2, S100B, KLK7, TM4SF3,
and OLFM4 had copy number gains and high expression levels (P 0.05) in no
recurrence vs. recurrence. CONCLUSIONS: Patients less than 60 years were signif-
icantly risky to get early relapse in colorectal cancer. In comparison to traditional
colorectal cancer gene chip, we would weight higher on EV12B (RR 4.622, 95% CI
1.741-12.270, p0.001), ATP2A2 (RR 4.688, 95% CI 1.443-15.232, p0.006), and S100B
(RR 11.521, 95% CI 2.688-49.377, p0.0001).
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OBJECTIVES: The 5-alpha-reductase inhibitors (5-ARIs), statins, aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) were previously reported to have pro-
tection effect for prostate cancer. The aim of this study was to simultaneously
investigate these drug effects on prostate cancer risk among benign prostatic hy-
perplasia (BPH) patients. METHODS: Newly diagnosed BPH patients (ICD-9-CM
code: 185 and A-code: A124) with at least one prescription of BPH medications
(5-ARIs, alpha-blockers) were identified from Taiwan Longitudinal Health Insur-
ance Database 2000 in 1998-2008. Drug usages of 5-ARIs, statins, aspirin, traditional
NSAIDs (tNSAIDs), and cyclooxygenase-2 (COX-2) selective inhibitors were com-
puted in terms of define daily dose (DDD), and were further categorized into high
and lose dose groups bymedians. The Cox regression was used to estimate hazard
ratios (HRs) for the occurrence of prostate cancer. Additional covariates in the
model included age, time-dependent covariates of drug usages and Charlson co-
morbidity score. RESULTS: There were 758 prostate cancers indicated from the
registry dataset for catastrophic illness patients from 41,955 BPH patients. The
analysis of all studied drugs showed significant protection HRs from univariate
analyses. After adjusting for covariates, the multivariable analysis showed signif-
icant protection effects on high dose of 5-ARIs (HR0.47, 95%CI 0.26-0.99), on high
dose of statins (HR0.56, 95%CI 0.38-0.83), on both low and high dose of tNSAIDs
(HR0.42, 95%CI 0.36-0.50; HR0.25, 95%CI 0.20-0.31), and on both low and high
dose of aspirin (HR0.73, 95%CI 0.60-0.88; HR0.34, 95%CI 0.26-0.45). The COX-2
selective inhibitors became not significant. CONCLUSIONS: The 5-ARIs, statins,
tNSAIDs, aspirin and COX-2 selective inhibitors have been separately investigated
their protection effects on the development of prostate cancer. Our results indi-
cated that the protection effects of 5-ARIs, statins, tNSAIDs and aspirin were inde-
pendently significant. In addition, the protection effect fromCOX-2 selective inhib-
itors was appeared to be confounded by other medication.
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OBJECTIVES: To evaluate the effect of Erythropoiesis stimulating agents (ESAs) use
on survival among colorectal cancer patients undergoing chemotherapy.
METHODS: This study was a nonconcurrent prospective cohort study using the
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